This Article Full Text (PDF) Other Versions of this Article: CVI.00090-07v1 14/8/984    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by García-Piñeres, A. Articles by Pinto, L. A. Search for Related Content PubMed PubMed Citation Articles by García-Piñeres, A. Articles by Pinto, L. A.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00090-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Cytokine and Chemokine Profiles following vaccination with HPV-16 L1 VLP

HPV Immunology Laboratory, SAIC-Frederick, Inc./NCI-Frederick, Frederick MD, USA, Division of Cancer Epidemiology and Genetics, National Institutes of Health, Bethesda, MD, USA, Johns Hopkins University, Baltimore, MD, USA, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA, Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Institutes of Health, Bethesda, MD, USA

^* To whom correspondence should be addressed. Email: lpinto{at}ncifcrf.gov.

	Abstract

To determine the systemic cytokine pattern induced by vaccination with HPV L1 VLP, we analyzed 22 different cytokines in culture supernatants of L1 VLP-stimulated PBMCs from vaccine (n=19) and placebo recipients (n=7) at month 0 and 2 after vaccination, using a multi-plex cytokine bead array. In vaccine recipients, incubation with L1 VLP in vitro led to a statistically significant increase in production of Th1 (GM-CSF, IL-2, IFN-, p<0.0007) and Th2 (IL-4, IL-5, IL-10, IL-13, p<0.0017) cytokines and the chemokine IP-10 (p=0.0021) at month 2 after immunization, when compared to levels seen prior vaccination. These responses were not seen in placebo recipients. Cytokine and neutralizing antibody responses to vaccination followed the same pattern, with the highest antibody responses seen for subjects with higher cytokine responses. Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV.